Inpharma 1618 - 15 Dec 2007

■ Deferasirox is effective for the treatment of iron-overloaded patients with sickle cell anaemia, concluderesearchers from the US.* In the 1-year core phase ofthe study, patients received deferasirox ordeferoxamine according to baseline liver ironconcentration; in the 4-year extension phase, patientscontinued treatment with deferasirox (n = 132) orcrossed over from deferoxamine to deferasirox (53). Inthe deferasirox cohort, patients who receiveddeferasirox at a dose of 5 or 10 mg/kg/daydemonstrated an increase from baseline in medianserum ferritin (SF) levels at 12 months (+50 ng/mL);SF levels gradually declined and reached baseline at24 months, following a dosage increase toapproximately 20 mg/kg/day. Patients who initiallyreceived deferasirox at a dosage of 20 or 30 mg/kg/dayhad SF levels that were maintained or reduced frombaseline.* This study was presented at the 49th Annual Meeting andExposition of the American Society of Hematology

Vichinsky E, et al. Long-term efficacy and safety of deferasirox (Exjade Rm,ICL670), a once-daily iron chelator, in patients with sickle cell disease. Blood110: 995 (plus oral presentation) abstr. 3395, No. 11, Part 1, 16 Nov2007 801096059

1

Inpharma 15 Dec 2007 No. 16181173-8324/10/1618-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved